NIKE Down Over 8%, on Track for Lowest Close Since September 2023 — Data Talk
NIKE, Inc. Class B (NKE) is currently at $92.40, down $8.42 or 8.35%
--Would be lowest close since Sept. 28, 2023, when it closed at $89.63
--On pace for largest percent decrease since Dec. 22, 2023, when it fell 11.83%
--Snaps a three day winning streak
--Down 11.09% month-to-date
--Down 14.89% year-to-date
--Down 47.95% from its all-time closing high of $177.51 on Nov. 5, 2021
--Down 23.45% from 52 weeks ago (March 24, 2023), when it closed at $120.71
--Down 27.77% from its 52-week closing high of $127.92 on May 1, 2023
--Up 3.33% from its 52-week closing low of $89.42 on Sept. 27, 2023
--Traded as low as $92.25; lowest intraday level since Sept. 28, 2023, when it hit $88.66
--Down 8.5% at today's intraday low; largest intraday percent decrease since Dec. 22, 2023, when it fell as much as 12.31%
--Worst performer in the DJIA today
--Second worst performer in the S&P 500 today
--Third most active stock in the S&P 500 today
--Subtracted 55.16 points from the DJIA so far today
All data as of 9:54:58 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
March 22, 2024 10:12 ET (14:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track